Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Mar 05, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | -- | |
| Feb 05, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | $5.96 | 365,517 | |
| Feb 05, 2020 | Director, Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $10.01 | 363,017 | |
| Feb 05, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 10,000 | |
| Jan 09, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | $5.96 | 347,695 | |
| Jan 09, 2020 | Director, Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $10.01 | 345,195 | |
| Jan 09, 2020 | Director, Chief Operating Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 20,000 | |
| Sep 14, 2015 | Vice President Finance | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $18.08 | 5,688 | |
| Jul 13, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | $15.00 | 30,187 | |
| Jul 13, 2015 | SVP, Pharmacology & Biology | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $15.00 | 27,687 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.